Abstract
Background: Prostate cancer (PCa) is the second cause of mortality in men worldwide. The prostate-specific antigen (PSA) test is routinely adopted in diagnosis; nevertheless more reliable biomarkers are continuously under investigation by monitoring the release of molecules into the bloodstream. The serum protein profiles appear to provide cancer-specific fingerprints that help to discriminate patients (especially with low PSA level) from controls, improving the performance of existing clinical tests. Methods: Samples from healthy controls and PCa patients with low (≤. 4. ng/mL) and high PSA (>. 4. ng/mL) levels were analyzed by MALDI profiling, and by a multi fractionation approach coupled to ESI-MS for peaks identification. Results: MALDI profiling achieved to detect 10 and 14 changed peaks (p-value
| Original language | English |
|---|---|
| Pages (from-to) | 42-49 |
| Number of pages | 8 |
| Journal | Clinica Chimica Acta |
| Volume | 439 |
| DOIs | |
| Publication status | Published - Oct 12 2014 |
Fingerprint
Keywords
- Complement C3f
- Immunodepletion
- MALDI profiling
- Prostate cancer
- Prostate-specific antigen
ASJC Scopus subject areas
- Biochemistry
- Clinical Biochemistry
- Biochemistry, medical
- Medicine(all)
Cite this
A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification. / Fania, Chiara; Sogno, Ilaria; Vasso, Michele; Torretta, Enrica; Leone, Roberta; Bruno, Antonino; Consonni, Paolo; Albini, Adriana; Gelfi, Cecilia.
In: Clinica Chimica Acta, Vol. 439, 12.10.2014, p. 42-49.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification
AU - Fania, Chiara
AU - Sogno, Ilaria
AU - Vasso, Michele
AU - Torretta, Enrica
AU - Leone, Roberta
AU - Bruno, Antonino
AU - Consonni, Paolo
AU - Albini, Adriana
AU - Gelfi, Cecilia
PY - 2014/10/12
Y1 - 2014/10/12
N2 - Background: Prostate cancer (PCa) is the second cause of mortality in men worldwide. The prostate-specific antigen (PSA) test is routinely adopted in diagnosis; nevertheless more reliable biomarkers are continuously under investigation by monitoring the release of molecules into the bloodstream. The serum protein profiles appear to provide cancer-specific fingerprints that help to discriminate patients (especially with low PSA level) from controls, improving the performance of existing clinical tests. Methods: Samples from healthy controls and PCa patients with low (≤. 4. ng/mL) and high PSA (>. 4. ng/mL) levels were analyzed by MALDI profiling, and by a multi fractionation approach coupled to ESI-MS for peaks identification. Results: MALDI profiling achieved to detect 10 and 14 changed peaks (p-value
AB - Background: Prostate cancer (PCa) is the second cause of mortality in men worldwide. The prostate-specific antigen (PSA) test is routinely adopted in diagnosis; nevertheless more reliable biomarkers are continuously under investigation by monitoring the release of molecules into the bloodstream. The serum protein profiles appear to provide cancer-specific fingerprints that help to discriminate patients (especially with low PSA level) from controls, improving the performance of existing clinical tests. Methods: Samples from healthy controls and PCa patients with low (≤. 4. ng/mL) and high PSA (>. 4. ng/mL) levels were analyzed by MALDI profiling, and by a multi fractionation approach coupled to ESI-MS for peaks identification. Results: MALDI profiling achieved to detect 10 and 14 changed peaks (p-value
KW - Complement C3f
KW - Immunodepletion
KW - MALDI profiling
KW - Prostate cancer
KW - Prostate-specific antigen
UR - http://www.scopus.com/inward/record.url?scp=84910051031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84910051031&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2014.10.003
DO - 10.1016/j.cca.2014.10.003
M3 - Article
VL - 439
SP - 42
EP - 49
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
SN - 0009-8981
ER -